CytoImmune Therapeutics Secures ALPPL2 Portfolio License: A New Milestone in Advancing Cell Therapy Solutions
TOA BAJA, Puerto Rico (PRWEB) August 03, 2023 -- CytoImmune Therapeutics, a leading biopharmaceutical company specializing in cell therapy development and manufacturing services, is proud to announce its acquisition of a license to the ALPPL2 portfolio from Flame Biosciences. This strategic acquisition expands CytoImmune’s capabilities in the development of allogeneic natural killer (NK) cell technologies, embracing a spectrum that includes chimeric antigen receptor T cells and NK cells, antibody drug conjugates (ADC), bispecific, and monoclonal antibodies.
The ALPPL2 portfolio consists of highly specific and targetable tumor cell surface antigens, showcasing compelling potential in the development of novel therapies against various types of solid tumors with the potential for multiple orphan drug designations. With the acquisition of this license, CytoImmune fortifies its role as a vital collaborator for biotechnology firms pioneering cell therapy and delivering groundbreaking treatments to those most in need.
"We are excited to integrate the ALPPL2 portfolio into our development and manufacturing services," says José Eduardo Vidal, Ph.D., Chief Executive Officer of CytoImmune Therapeutics. "This acquisition will empower us to present our clients with an even more diversified array of cell therapy solutions, contributing substantially to the growth of off-the-shelf allogeneic cell therapy space and improving the lives of cancer patients."
CytoImmune's state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico, propels the development and commercialization of cutting-edge NK cell therapies stemming from the ALPPL2 portfolio. Harnessing the company’s proprietary, robust, and thoroughly characterized NK cell expansion and engineering technologies, CytoImmune aims to transcend conventional boundaries and deliver unparalleled cell therapy solutions to its partners.
About CytoImmune Therapeutics:
CytoImmune Therapeutics is at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials. In addition, we are now offering cell therapy development and clinical manufacturing services to both biotechnology companies and academia. Our state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico, is custom built to support the development and commercialization of cutting-edge T cell or NK cell therapies. At CytoImmune, we are dedicated to fostering collaborations that drive the future of cell therapy and improve the lives of cancer patients. Discover how our expertise in cell therapy development and clinical manufacturing can accelerate your path to success. For additional information, please visit: Cytoimmune.com
Media Contact:
Albert Stichka
Albert Stichka, Elkordy Global Strategies, 1 6192544768, [email protected]
Share this article